Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
MEOBF's Cash-to-Debt is ranked higher than
92% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. MEOBF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MEOBF' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.77
MEOBF's Equity-to-Asset is ranked higher than
63% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MEOBF: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
MEOBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.69 Max: 0.77
Current: 0.77
0.6
0.77
Altman Z-Score: 1.78
WACC vs ROIC
13.19%
-24.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -88.92
MEOBF's Operating Margin % is ranked higher than
51% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. MEOBF: -88.92 )
Ranked among companies with meaningful Operating Margin % only.
MEOBF' s Operating Margin % Range Over the Past 10 Years
Min: -1357.78  Med: -361.59 Max: 77.54
Current: -88.92
-1357.78
77.54
Net Margin % -24.81
MEOBF's Net Margin % is ranked higher than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. MEOBF: -24.81 )
Ranked among companies with meaningful Net Margin % only.
MEOBF' s Net Margin % Range Over the Past 10 Years
Min: -1932.16  Med: -404.99 Max: 74.93
Current: -24.81
-1932.16
74.93
ROE % -1.57
MEOBF's ROE % is ranked higher than
74% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. MEOBF: -1.57 )
Ranked among companies with meaningful ROE % only.
MEOBF' s ROE % Range Over the Past 10 Years
Min: -51.29  Med: -17.63 Max: 32.19
Current: -1.57
-51.29
32.19
ROA % -1.11
MEOBF's ROA % is ranked higher than
76% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. MEOBF: -1.11 )
Ranked among companies with meaningful ROA % only.
MEOBF' s ROA % Range Over the Past 10 Years
Min: -48.74  Med: -11.27 Max: 22.31
Current: -1.11
-48.74
22.31
ROC (Joel Greenblatt) % -2287.98
MEOBF's ROC (Joel Greenblatt) % is ranked lower than
73% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. MEOBF: -2287.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MEOBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8672.2  Med: -3187.57 Max: 20767.8
Current: -2287.98
-8672.2
20767.8
3-Year Revenue Growth Rate 8.60
MEOBF's 3-Year Revenue Growth Rate is ranked higher than
56% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. MEOBF: 8.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MEOBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.2  Med: -3.9 Max: 296.9
Current: 8.6
-46.2
296.9
3-Year EBITDA Growth Rate 11.70
MEOBF's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MEOBF: 11.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MEOBF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.6  Med: 20.4 Max: 44.2
Current: 11.7
-7.6
44.2
3-Year EPS without NRI Growth Rate -59.50
MEOBF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MEOBF: -59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MEOBF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: 15.5 Max: 50
Current: -59.5
-59.5
50
GuruFocus has detected 1 Warning Sign with Mesoblast Ltd $MEOBF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MEOBF's 30-Y Financials

Financials (Next Earnings Date: 2017-08-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711 
Compare:NAS:ACOR, NAS:OMER, NAS:JNCE, NYSE:MYOV, NAS:ADRO, NAS:MGNX, OTCPK:IPHYF, NAS:ANIK, NAS:KERX, NAS:EDIT, NAS:AMRI, NAS:LJPC, NAS:ESPR, NYSE:BHVN, NAS:ACRS, NAS:AMAG, NAS:TGTX, NAS:CYTK, NAS:BYSI, NAS:VNDA » details
Traded in other countries:MSB.Australia, LWB.Germany, MESO.USA,
Headquarter Location:Australia
Mesoblast Ltd is engaged in the development of regenerative medicine products. The Company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.

Mesoblast is developing adult stem cell therapies based on its proprietary mesenchymal precursor stem cell and culture-expanded mesenchymal stem cell technology platforms. It has nine clinical trial programs across four major areas (cardiovascular, spine disease, immunologic/inflammatory, and cancer) targeting chronic diseases affecting large populations.

Ratios

vs
industry
vs
history
PB Ratio 1.38
MEOBF's PB Ratio is ranked higher than
86% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. MEOBF: 1.38 )
Ranked among companies with meaningful PB Ratio only.
MEOBF' s PB Ratio Range Over the Past 10 Years
Min: 0.57  Med: 0.97 Max: 2.24
Current: 1.38
0.57
2.24
PS Ratio 20.88
MEOBF's PS Ratio is ranked lower than
61% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. MEOBF: 20.88 )
Ranked among companies with meaningful PS Ratio only.
MEOBF' s PS Ratio Range Over the Past 10 Years
Min: 6.67  Med: 23.56 Max: 261.18
Current: 20.88
6.67
261.18
EV-to-EBIT -7.49
MEOBF's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. MEOBF: -7.49 )
Ranked among companies with meaningful EV-to-EBIT only.
MEOBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -46.2  Med: -6.8 Max: -2.3
Current: -7.49
-46.2
-2.3
EV-to-EBITDA -7.61
MEOBF's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. MEOBF: -7.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
MEOBF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.2  Med: -6.9 Max: -2.3
Current: -7.61
-46.2
-2.3
Current Ratio 2.30
MEOBF's Current Ratio is ranked lower than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. MEOBF: 2.30 )
Ranked among companies with meaningful Current Ratio only.
MEOBF' s Current Ratio Range Over the Past 10 Years
Min: 2.26  Med: 3.02 Max: 6.56
Current: 2.3
2.26
6.56
Quick Ratio 2.30
MEOBF's Quick Ratio is ranked lower than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MEOBF: 2.30 )
Ranked among companies with meaningful Quick Ratio only.
MEOBF' s Quick Ratio Range Over the Past 10 Years
Min: 2.26  Med: 3.02 Max: 6.56
Current: 2.3
2.26
6.56
Days Sales Outstanding 6.61
MEOBF's Days Sales Outstanding is ranked higher than
91% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. MEOBF: 6.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
MEOBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.07  Med: 4.27 Max: 110.87
Current: 6.61
0.07
110.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
MEOBF's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. MEOBF: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MEOBF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -13.3 Max: -5.6
Current: -8.9
-27.6
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 8.34
MEOBF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. MEOBF: 8.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MEOBF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.34
Current: 8.34
0
8.34
Price-to-Median-PS-Value 0.88
MEOBF's Price-to-Median-PS-Value is ranked higher than
65% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. MEOBF: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MEOBF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.35 Max: 10.98
Current: 0.88
0.28
10.98
Earnings Yield (Greenblatt) % -13.35
MEOBF's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. MEOBF: -13.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MEOBF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -69.25  Med: 5.8 Max: 7.2
Current: -13.35
-69.25
7.2

More Statistics

Revenue (TTM) (Mil) $31.97
EPS (TTM) $ -5.20
Beta2.99
Short Percentage of Float0.00%
52-Week Range $0.70 - 2.42
Shares Outstanding (Mil)401.70

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 6 9 23
EPS ($) -0.18 -0.14 -0.16
EPS without NRI ($) -0.18 -0.14 -0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MEOBF

Headlines

Articles On GuruFocus.com
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Apr 10 2017 
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activit Apr 06 2017 
FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell T Apr 03 2017 
Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Mar 31 2017 
Mesoblast Raises US$40 Million Mar 27 2017 
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast Mar 15 2017 
FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Ve Mar 07 2017 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 

More From Other Websites
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart... Apr 10 2017
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development... Apr 06 2017
FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell... Apr 03 2017
Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Phase... Mar 31 2017
Mesoblast Raises US$40 Million Mar 27 2017
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s... Mar 15 2017
Mesoblast (MESO) Shares March Higher, Can It Continue? Mar 14 2017
FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus... Mar 07 2017
Mesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December... Feb 26 2017
Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast Feb 24 2017
Mallinckrodt enters $21 million equity purchase agreement with Mesoblast Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat